LPGAT1 and Hepatic steatosis: Unlike synthetic MTP inhibitors, miR-30c did not cause hepatic steatosis, likely due to the simultaneous downregulation of genes involved in de novo lipid synthesis, such as lysophosphatidylglycerol acyltransferase 1 (LPGAT1) [27].